Prognostic value of cetuximab‐related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Study Group
Sebastian Stintzing(University of Southern California), Volker Heinemann(Comprehensive Cancer Center Vienna), Dominik Paul Modest, Andreas Jung(German Cancer Research Center), Andreas Wollenberg(Vrije Universiteit Brussel), Jens Neumann(Ludwig-Maximilians-Universität München), Nicolas Moosmann(Praxis für Hämatologie und Onkologie), Clemens Gießen, Thomas Kirchner(Friedrich-Alexander-Universität Erlangen-Nürnberg), Rüdiger P. Laubender(Zimmer Biomet (Germany)), Christine Kapaun
Cited by 81
Related Papers
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Prognostic and Predictive Relevance of Primary Tumor Location in Patients With <i>RAS </i>Wild-Type Metastatic Colorectal Cancer
|JAMA Oncology|2016|722
β-Catenin Regulates the Expression of the Matrix Metalloproteinase-7 in Human Colorectal Cancer
|American Journal Of Pathology|1999|663